Melanoma Molecular Maps Projects



Title: Immunosuppressive circuits in anticancer adaptive immune response
Legend: Schematic view of immunosuppressive circuits (red arrows and molecules) that hamper an effective adaptive immune response against cancer. ARG: arginase; B7-1: CD80 (CD28 and CTLA4 ligand); B7-2: CD86 (CD28 and CTLA4 ligand); CD4: HTL co-receptor for HLA class II; CD8: CTL co-receptor for HLA class I; CD25: IL-2 receptor; CD28: B7 receptor (costimulatory pathway); CD40: CD40L receptor; CD40L: CD40 ligand; CD91: heat shock protein (HSP) receptor; CD200; CTL: cytotoxic T lymphocyte; CTLA4: cytotoxic T lymphocyte associated antigen 4 (B7 receptor, CD152) (coinhibitory pathway); DC: dendritic cell; FOXP3: Forkhead box P3 (transcription factor); HLA-I / HLA-II: human leukocyte antigen class I / II; HTL: helper T lymphocyte; IDO: indoleamine 2,3-dioxygenase; IFNg: interferon gamma; IL-2: interleukin-2 (IL2); IL-10: interleukin-10 (IL10); IL-12: interleukin-12 (IL12); iNOS: inducible nitric oxide synthase; MDSC: myeloid derived suppressor cell; PD-1: PD-L1 receptor (coinhibitory pathway) (PD1, CD279, PDCD1, programmed cell death 1); PDL-1: PD-1 ligand (CD274, programmed cell death 1 ligand 1, B7-H, B7H1, PDL1); PGE2: prostaglandin E2; proteasome; STAT3: signal transducer and activator of transcription 3; TAA: tumor associated antigen; TAP: transporter associated with antigen processing proteins; TCR: T cell receptor; TGFb: transforming growth factor beta; TLR: toll like receptor; Treg: regulatory T cell; VEGF: vascular endothelial growth factor. REFERENCES: [1] Rabinovich GA et al, Annu Rev Immunol 2007, 25:267-96. [2] Mocellin S et al, Med Res Rev 2007, 27:317-52. [3] Reiman JM et al, Semin Cancer Biol 2007, 17:275-87. Figure #39
Author: The MMMP Team (updated: December 2007)

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

NCBI's Disclaimer and Copyright notice